malaria threats map - world health organization...malaria threats map across surveys, the criteria...
TRANSCRIPT
Malaria Threats Map
Malaria Policy Advisory Committee Meeting
Geneva, Switzerland
18 October 2017
1. Scope
2. Progress
3. Status
4. Data overview
5. Demonstration
6. Plans
Overview
Scope
Vector insecticide resistance (bioassays, mechanisms) hrp2/3 gene deletions (single and mixed) Antimalarial drug efficacy and drug resistance (therapeutic efficacy studies (TES), molecular markers)
Biological challenges to malaria control and elimination
Progress
• Extra data ie. 2016/2017
• Significant refinement of:
• Data filters
• Dynamic legends
• Symbols ie. toggle for country/site data
• Popup content ie. text, tables and figures
• Geographies navigator
• Formulated explanatory text
• Translated all content ie. French, Spanish
Updates since MPAC March 2017
Status
• 98% completed
• Pending: minor updates to functionality and aesthetics
• Launch: anticipated by end October 2017
As of 18 October 2017
Data overview
Bioassays (standard only) discriminating concentration intensity concentration
Mechanisms (biochemical, molecular, synergist-insecticide assays) metabolic - mono oxygenases, esterases, GSTs target-site mutations - kdr , Ace1R
Vector insecticide resistance 1949 – 2017
bioassays (all), mechanisms 91 countries = 29,137 tests
GMP Databases
hrp2/3 gene deletions 1996 – 2017
suspected, confirmed 26 countries = 131 survey areas
Drug efficacy & drug resistance 2004 – 2017
TES results, molecular markers 78 countries = 2,133 studies
Vector insecticide resistance 2010 – 2017
bioassays (standard), mechanisms 83 countries = 18,712 tests
hrp2/3 gene deletions 1998 – 2017 confirmed
24 countries = 125 survey areas
Drug efficacy & drug resistance 2010 – 2017
TES results, molecular markers 71 countries = 1,006 studies
Malaria Threats Map
Data overview
Type of deletion pfhrp2 pfhrp2 and 3
Survey type Cross sectional Convenience/screening Case report DHS
Clinical status symptomatic asymptomatic mixed or unknown
Vector insecticide resistance 1949 – 2017
bioassays (all), mechanisms 91 countries = 29,137 tests
GMP Databases
hrp2/3 gene deletions 1996 – 2017
suspected, confirmed 26 countries = 131 survey areas
Drug efficacy & drug resistance 2004 – 2017
TES results, molecular markers 78 countries = 2,133 studies
Vector insecticide resistance 2010 – 2017
bioassays (standard), mechanisms 83 countries = 18,712 tests
hrp2/3 gene deletions 1998 – 2017 confirmed
24 countries = 125 survey areas
Drug efficacy & drug resistance 2010 – 2017
TES results, molecular markers 71 countries = 1,006 studies
Malaria Threats Map
Across surveys, the criteria for selecting samples to test for pfhrp2/3 deletions varies. Percentage of samples tested with deletions is presented
Data overview
Therapeutic efficacy studies P. falciparum P. vivax
Molecular marker studies K13 Pfcrt (next version)
Vector insecticide resistance 1949 – 2017
bioassays (all), mechanisms 91 countries = 29,137 tests
GMP Databases
hrp2/3 gene deletions 1996 – 2017
suspected, confirmed 26 countries = 131 survey areas
Drug efficacy & drug resistance 2004 – 2017
TES results, molecular markers 78 countries = 2,133 studies
Vector insecticide resistance 2010 – 2017
bioassays (standard), mechanisms 83 countries = 18,712 tests
hrp2/3 gene deletions 1998 – 2017 confirmed
24 countries = 125 survey areas
Drug efficacy & drug resistance 2010 – 2017
TES results, molecular markers 71 countries = 1,006 studies
Malaria Threats Map
Live demonstration
Live demonstration
Live demonstration
Live demonstration
Mobile compatibility: pending
Interim
• Finalise pending updates
• Shift to WHO server and launch
• Beta test and address arising issues (eg. bugs)
• Conduct consultations to define priorities for optimising / expanding
Phase II development
Potential options:
• Regional symbols and pop-ups (to compare across countries)
• Data upload / download
• Automated summary report
• Print functionality
• Mobile compatibility
Plans
Thank you
For further information:
• The URL to the Malaria Threats Map beta application will be circulated widely upon launch
Tessa Knox: [email protected]
Jane Cunningham: [email protected]
Amy Barrette: [email protected]